Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
Russian scientists are working on the development of an innovative drug against hepatitis B that can be considered as a breakthrough in the global market for such drugs, according to scientists and experts of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 30 July 2018
Pharmaceutical
Both Russian and global pharmaceutical producers operating in the local market have called on the national government to ease the process of registration of drugs in Russia, reports The Pharma Letter’s local correspondent. 30 July 2018
Biotechnology
Shanghai, China-based biotech startup I-Mab Biopharmaplans to file an Investigational New Drug (IND) application in the USA later this year for three candidates, including two for oncology and one for autoimmune diseases, said I-Mab Biopharma chief executive Jingwu Zang last week in Shanghai at a media event for licensing out a lgG-like, bispecific monoclonal antibody (Bsab) to the South Korean biotech startup ABL Bio. 30 July 2018
Pharmaceutical
Last week saw the surprise announcement from Gilead Sciences that both its chief executive and chairman are to leave the company. On the M&A front last week, Sangamo Therapeutics decision to acquire the small French biotech TxCell featured. Regulatory news included a US Food and Drug Administration approval for Agios rare cancer treatment Tibsovo, while an FDA advisory panel voted against approval of GlaxoSmithKline’s Nucala for COPD. Also disappointing, was the latest data on Biogen and Eisai’s Alzheimer’s candidate BAN2401. 29 July 2018
Generics
Ahead of World Hepatitis Day on July 28, the Indian government is to give away free antiviral for hepatitis C to tackle liver cancer. With $87.50 million approved for the current financial year, the government is all set to launch an ambitious National Viral Hepatitis Control Program, reports The Pharma Letter’s India correspondent. 29 July 2018
Pharmaceutical
Dermatology specialist Botanix Pharmaceuticals has named Stephane Levy its chief medical officer. 27 July 2018
Biotechnology
In the 1980s, technologies such as DNA editing started to mature, creating a range of sophisticated and transformative therapeutic techniques - and a race to secure funding, technologies and expertise. 27 July 2018
Biotechnology
Along with announcing analysts’ expectation-beating financials, leading biotech firm Amgen's outlined planned executive succession to address upcoming departures of two executive vice presidents. 27 July 2018
Biotechnology
UCB rose 1.2% on Thursday after it published financial results for the first half of 2018. The Belgian drugmaker, which specializes in immunology and neurology, reported 5% sales increases and a 2% rise in overall revenue over the first half of 2017. 26 July 2018
Biotechnology
As was widely expected, US biotech Gilead Sciences late yesterday posted another quarter of falling sales and profits, but surprised with the announcement that both its chief executive and chairman were departing from the company. 26 July 2018
Pharmaceutical
The General Data Protection Regulation (GDPR) came into force on May 25, 2018. In an Expert View piece, Christian Hebenstreit — general manager and senior vice president at Medidata Solutions — explores the ramifications that this far-reaching change to data regulation could have on the life sciences industry. 25 July 2018
Generics
Janssen Pharmaceuticals, part of US health care giant Johnson & Johnson, is considering initiating legal proceedings against Russian drugmaker Pharmsyntez for the registration of an analogue of an anti-HIV rilpivirine drug, the patent for which belongs to Janssen, reports The Pharma Letter’s local correspondent. 24 July 2018
Pharmaceutical
Japanese pharma major Astellas Pharma is making leadership changes affecting its operations in the Americas. 24 July 2018
Pharmaceutical
For several years, pharma analysts have predicted varying degrees of impact from nascent blockchain technologies. While some suggest wholesale revolution is in the offing, others anticipate more incremental evolution for a conservative industry that is traditionally resistant to change. 23 July 2018
Biotechnology
It’s been a rapid journey for the biopharma industry over the last few years. We’ve seen the industry stagger to its feet – surpassing notable early setbacks caused by lack of control over hyperallergenic drugs. 20 July 2018
Pharmaceutical
Germany’s Merck KGaA has hired Dr Maria Rivas as senior vice president, head of global medical affairs. 17 July 2018
Pharmaceutical
Having recently acquired the oncology business of Shire for $2.4 billion, leading independent French drugmaker Servier has now also acquired a senior executive of the company. 17 July 2018
Biotechnology
OncoSec Medical, a company developing intratumoral cancer immunotherapies, today announced the appointment of Sara Bonstein as Chief Financial Officer and Chief Operating Officer. 16 July 2018
Biotechnology
USA-based biotech CytoDyn says it has signed a non-binding letter of intent regarding a proposed acquisition of intellectual property and other assets of ProstaGene. 16 July 2018
Pharmaceutical
Russia’s President Vladimir Putin has instructed the national government to consider the possibility of reforming the current system of state purchases of drugs in Russia, according to recent statements of the press-service of the Russian Presidential Administration, reports The Pharma Letter’s local correspondent. 16 July 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze